文献速递系统性红斑狼疮

SLE患者使用免疫抑制剂的心血管疾病事件风险比较

Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究基于Medicaid Analytic eXtract(2000-2012)数据,采用倾向评分匹配比较SLE患者启用MMF、CYC或AZA后首次CVD事件风险。主要分析中MMF vs CYC和MMF vs AZA的CVD风险均无统计学显著降低,仅在12个月ITT分析中MMF较AZA新用户CVD风险更低。

要点

  • 主要分析中MMF vs CYC的首次CVD事件风险无显著降低(HRs.d 0.72, 95%CI 0.37-1.39)。
  • 主要分析中MMF vs AZA的首次CVD事件风险无显著降低(HRs.d 0.88, 95%CI 0.59-1.32)。
  • 12个月ITT分析中MMF较AZA新用户首次CVD事件风险更低(HRs.d 0.68, 95%CI 0.47-0.98)。

核心结论

  • 在倾向评分匹配的头对头分析中,SLE患者启用MMF vs CYC或AZA的CVD事件风险无统计学显著降低,仅12个月ITT分析中MMF vs AZA显示风险更低,提示长期使用可能获益。

研究设计与样本

  • 使用Medicaid Analytic eXtract(2000-2012)数据,纳入启用MMF、CYC或AZA的成人SLE患者,采用倾向评分1:1匹配,主要分析为as-treated,次要分析为6个月和12个月ITT。

主要发现

  • MMF vs CYC匹配680对,首次CVD事件风险HRs.d 0.72(95%CI 0.37, 1.39),无统计学显著降低。
  • MMF vs AZA匹配1871对,首次CVD事件风险HRs.d 0.88(95%CI 0.59, 1.32),无统计学显著降低。
  • 12个月ITT分析中,MMF较AZA新用户首次CVD事件风险更低,HRs.d 0.68(95%CI 0.47, 0.98)。

临床怎么用

  • 在SLE患者选择免疫抑制剂时,MMF相较于CYC或AZA未显示明确的短期CVD风险降低,但12个月ITT分析提示MMF长期使用可能具有心血管保护获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: SLE patients have elevated cardiovascular disease (CVD) risk, but it is unclear whether this risk is affected by choice of immunosuppressive drug. We compared CVD risks among SLE patients starting MMF, CYC or AZA. METHODS: Using Medicaid Analytic eXtract (2000-2012), adult SLE patients starting MMF, CYC or AZA were identified and propensity scores (PS) were estimated for receipt of MMF vs CYC and MMF vs AZA. We examined rates of first CVD event (primary outcome), all-cause mortality, and a composite of first CVD event and all-cause mortality (secondary outcomes). After 1:1 PS-matching, Fine-Gray regression models estimated subdistribution hazard ratios (HRs.d.) for risk of CVD events. Cox regression models estimated HRs for all-cause mortality. The primary analysis was as-treated; 6- and 12-month intention-to-treat (ITT) analyses were secondary. RESULTS: We studied 680 PS-matched pairs of patients with SLE initiating MMF vs CYC and 1871 pairs initiating MMF vs AZA. Risk of first CVD event was non-significantly reduced for MMF vs CYC [HRs.d 0.72 (95% CI: 0.37, 1.39)] and for MMF vs AZA [HRs.d 0.88 (95% CI: 0.59, 1.32)] groups. In the 12-month ITT, first CVD event risk was lower among MMF than AZA new users [HRs.d 0.68 (95% CI: 0.47, 0.98)]. CONCLUSION: In this head-to-head PS-matched analysis, CVD event risks among SLE patients starting MMF vs CYC or AZA were not statistically reduced except in one 12-month ITT analysis of MMF vs AZA, suggesting longer-term use may convey benefit. Further studies of potential cardioprotective benefit of MMF are necessary.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Choi MY, Li D, Feldman CH, et al. Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications. Rheumatology (Oxford). 2021. PMID: 33369672. doi:10.1093/rheumatology/keaa862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。